Research comparison
TB-500 vs BPC-157
Side-by-side comparison of research status, mechanisms, pharmacokinetics, and administration routes.
Research Status
Preclinical
Preclinical
Half-Life
~6–8 hours
~4 hours (subcutaneous); oral stability under investigation
Mol. Weight
4963.44 Da
1419.55 Da
Admin Routes
subcutaneous, intramuscular
subcutaneous, intramuscular, oral
Categories
Healing & Recovery, Muscle & Performance, Cardiovascular
Healing & Recovery, Pain & Inflammation, Cognitive Enhancement
Interaction
synergistic
BPC-157 and TB-500 have complementary tissue-repair mechanisms — BPC-157 promotes angiogenesis and tendon healing while TB-500 enhances actin-driven cell migration. Together they exhibit amplified regenerative effects beyond either alone.
well-documented
Mechanism
Pharmacokinetics
Research Findings
Safety
Related comparisons